Put the Use of SGLT2 Inhibitors for Heart Failure In Perspective
November 2019
You'll hear debate about using an SGLT2 inhibitor (dapagliflozin, etc) to treat heart failure...in patients withOUT diabetes.
Prior evidence shows that patients WITH diabetes and CV disease or CV risks have fewer heart failure hospitalizations with canagliflozin (Invokana), dapagliflozin (Farxiga), or empagliflozin (Jardiance).
New evidence suggests dapagliflozin may benefit some heart failure patients...whether or not they have type 2 diabetes.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote